“James L. Martin, chairman of the 60 Plus Association, a seniors advocacy group, applauded the Food and Drug Administration's (FDA) decision to remove unapproved colchicine products from the market, and called on drug manufacturers, distributors and pharmacies to help the FDA protect patients from unapproved drugs.
…
“On behalf of 60 Plus, I would like to thank the FDA for calling for the removal of unapproved colchicine from pharmacy shelves. Patients are now safer because of the agency's actions,” Martin said. “It is important, however, to remember that thousands of unapproved drugs are still available and that all involved in the drug distribution chain must work to protect patients from potential dangers posed by these drugs. That means the FDA must enhance its enforcement of the Unapproved Drugs Initiative by removing the remainder of unapproved drugs when approved versions are available.”